
India approves first dengue vaccine Qdenga for 4-60 age group
The story in brief
India’s first dengue vaccine, Qdenga, has been approved by the DCGI for use in people aged 4 to 60. Developed by Takeda, it marks a key milestone in combating dengue, a major public health issue. The approval expands access to preventive measures for children and adults. The DCGI, India’s drug regulator, gave the green light after thorough review. This development is expected to boost dengue prevention efforts nationwide.